{"Clinical Trial ID": "NCT00368875", "Intervention": ["INTERVENTION 1:", "Phase I", "The dose of vorinostat (200 or 300 mg BID) was assigned at the time of registration. Vorinostat was administered orally twice daily on days 1-3, 8-10 and 15-17 of each 28-day cycle.", "All patients also received paclitaxel at 90 mg/m2 as a one-hour infusion on days 2, 9 and 16 of each 28-day cycle. Bevacizumab was administered on day 2 and day 16 of the 28-day cycle at 10 mg/kg dose."], "Eligibility": ["Incorporation criteria:", "\u2022 Breast adenocarcinoma confirmed by histology or cytology; effective with version 2.2 (1/26/09), only patients with biopsy-accessible disease consenting to serial biopsy are eligible.", "A two-dimensional and/or one-dimensional, measurable indicator lesion must be present (patients with only one non-measurable disease are eligible for the Phase I trial only); all disease sites must be noted and monitored.", "ECOG Performance Status = < 1 (Karnofsky >= 70%)", "Absolute number of neutrophils >= 1,500/ul", "Platelets >= 100 000/ul", "Total bilirubin within normal institutional limits", "AST(SGOT)/ALT(SGPT) = < 2.5 x upper institutional limit of normal", "PTT and INR or PT < 1.5 x normal", "\u2022 Creatinine within normal institutional limits OR creatinine clearance >= mL/min/1.73 m^2 for patients with creatinine levels above institutional normal", "urinary proteins should be tested by urinary analysis to determine the ratio of urinary protein creatinine (UPC); for UPC > 0.5, a 24-hour urinary protein should be obtained and the rate should be < 1000 mg for patient registration;", "\u2022 LVEF must be at or above the lower institutional limit of the normal interval (on MUGA or Echo obtained within 12 weeks of registration, or within 4 weeks after the previous Herceptin)", "Not pregnant/lactation", "- Exclusion criteria:", "- Chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosourea or mitomycin C) prior to entry into the study", "There can't be any other investigative officers.", "History of allergic reactions attributed to compounds of chemical or biological composition similar to vorinostat or other agents used in the study (e.g., paciltaxel, bevacizumab, quinolones)", "\u2022 An uncontrolled intercurrent disease including, but not limited to, continuous or active infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, or psychiatric or social situations that would limit compliance with the requirements of the study."], "Results": ["Performance measures:", "The recommended dose of Phase II evaluated according to the common NIC terminology criteria for adverse events (CTCAE) Version 3.0 (Phase I)", "Dose-limiting toxins (TDLs) were defined as grade 3-4 febrile neutropenia, thrombocytopenia, and non-haematological toxicities attributed to treatment (nausea, vomiting, and diarrhoea would only be considered dose-limiting if not adequately controlled by treatment).", "Time limit: 28 days", "Results 1:", "Title of arm/group: Phase I", "The dose of vorinostat (200 or 300 mg BID) was assigned at the time of registration. Vorinostat was administered orally twice daily on days 1-3, 8-10 and 15-17 of each 28-day cycle.", "All patients also received paclitaxel at 90 mg/m2 as a one-hour infusion on days 2, 9 and 16 of each 28-day cycle. Bevacizumab was administered on day 2 and day 16 of the 28-day cycle at 10 mg/kg dose.", "Total number of participants analysed: 6", "Type of measurement: Number", "Unit of measurement: mg 300"], "Adverse Events": ["Undesirable Events 1:", "Total: 27/54 (50%)", "Neutropenia 15/54 (27.78%)", "Anemia 3/54 (5.56 per cent)", "Diarrhoea 3/54 (5.56%)", "Vomiting 4/54 (7.41%)", "Headache 3/54 (5.56%)", "Fatigue 10/54 (18.52 per cent)", "Neuropathy 12/54 (22.22%)", "Proteinuria 1/54 (1.85%)"]}